MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, February 17, 2018

Ipsen Announces Dysport® (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in Spasticity

Oral Presentations at the 2018 Annual Meeting of the Association of Academic Physiatrists (AAP) Provide Additional Data on the Safety and Efficacy of Dysport® in Adults with Upper and Lower Limb Spasticity and Children with Lower Limb Spasticity 

BASKING RIDGE, N.J., February 15, 2018 – Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), announced Dysport® (abobotulinumtoxinA) data will be presented today in two oral presentations at the annual meeting of the Association of Academic Physiatrists (AAP) being held in Atlanta, February 13-17, 2018. The oral presentations provide the outcomes of multiple Phase 3 studies that evaluated time to retreatment, as well as long-term treatment with Dysport® .

“The data being presented at this year’s AAP meeting indicate that Dysport® provides sustained spasticity relief for both adult and pediatric patients,” said David Cox, Vice President, US Medical Affairs, HEOR & Commercial Regulatory Affairs, Ipsen. “Improved outcomes from long-term therapy along with longer time between injections can be important factors in the management of these conditions, and we’re pleased to share these data to help inform physician and patient treatment decisions.”

In the first oral presentation, results from three randomized, placebo-controlled, double-blind Phase 3 studies of Dysport® evaluating time to retreatment in three patient groups showed that 37 percent of hemiparetic (post-stroke/traumatic brain injury) patients with adult upper limb spasticity (AULS), 20 percent of hemiparetic patients with adult lower limb spasticity (ALLS) and 74 percent of patients with pediatric (at least two years of age) lower limb spasticity (PLLS) due to cerebral palsy did not require reinjection until week 16 or later (Abstract #361196).

Learn more by clicking here



::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
SUBSCRIBE to our MS Learning Channel on YouTube: www.youtube.com/msviewsandnews
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

No comments: